TI Verbatim Consulting (TIVC) is a proven leader in workplace culture assessment, language services, and business support services. TIVC Inc. is an SBA 8(a) program participant, a Center for Verification and Evaluation (CVE) certified Service-Disabled Veteran-Owned Small Business, and an Economically Disadvantaged Women-Owned Small Business.
Founded in 2014 by Jean Ibañez Payne, a multilingual service-disabled Navy Veteran, TIVC pursues servant-style leadership and is heralded as a responsive and customer-oriented professional services company. Jean is the sole owner and has 25 years of experience in government and private industry. TIVC has current and former contracts with the departments and affiliated agencies of Energy, Defense, Treasury, Health and Human Services, Homeland Security, Justice, Defense Logistics Agency, National Aeronautics and Space Administration, Millennium Challenge Corporation, A. Bright Idea, Canon, and Dominion Energy and supports clients in Alabama, Arizona, Colorado, Kansas, Maryland, Mississippi, Missouri, South Carolina, Texas, Utah, Virginia, Washington D.C., and West Virginia.
To help people work better together.
Improve workplace culture, strengthen the understanding of ideas communicated in different languages, and provide superior people in support of administrative and technical goals.
Owner and CEO
Jean Ibañez Payne
Director, Human Resources & CEO Chief of Staff
Senior VP, Finance
Senior Director, Diversity, Equity & Inclusion
Veronica Lawrence Ortega
Director, Culture Assessments
Director, Program Management
Manager, Communications & Marketing
Manager, Captures & Proposals
Financial Analyst II
Business Account Specialist II
Culture & Data Analytic Specialist
Junior Contract Administrator
TIVC was granted an early-entry waiver into the SBA’s 8(a) Business Development Program.
TIVC’s founder and CEO, Jean Ibañez Payne, is a service-disabled Navy veteran. TIVC is a CVE-certified SDVOSB.
TIVC’s EDWOSB status was certified by the U.S. Women’s Chamber of Commerce.
TIVC achieved certification in November 2020 with zero adverse findings.